NEW YORK, July 23, 2026 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a global leader in women’s health and family building solutions, will report its financial results for the quarterly period ended June 30, 2026 after the close of the market on Thursday, August 6, 2026.
The company will host a conference call at 4:45 p.m. Eastern Time (1:45 p.m. Pacific Time) and issue a press release regarding its financial results prior to the start of the call.
Interested participants in the United States may access the conference call by dialing 1.866.825.7331 and using the passcode 265484. International participants may access the call by dialing 1.973.413.6106 and using the same passcode.
An audio replay of the call will be available through Thursday, August 13, 2026 and may be accessed by dialing 1.800.332.6854 (U.S. participants) or 1.973.528.0005 (international participants) with the passcode 265484.
A live webcast and archive of the call will be available from the Events and Presentations section of the Company’s website at http://investors.progyny.com.
About Progyny
Progyny (Nasdaq: PGNY) is a global leader in women's health and family building solutions, trusted by the nation's leading employers, health plans and benefit purchasers. We envision a world where everyone can realize their dreams of family and ideal health. Our outcomes prove that comprehensive, inclusive and intentionally designed solutions simultaneously benefit employers, patients, and physicians.
Our benefits solution empowers patients with concierge support, coaching, education, and digital tools; provides access to a premier network of fertility and women's health specialists who use the latest science and technologies; drives optimal clinical outcomes; and reduces healthcare costs.
Headquartered in New York City, Progyny has been recognized for its leadership and growth as a TIME100 Most Influential Company, CNBC Disruptor 50, Modern Healthcare’s Best Places to Work in Healthcare, Forbes' Best Employers, Financial Times Fastest Growing Companies, INC. 5000, INC. Power Partners and Crain’s Fast 50 for NYC. For more information, visit www.progyny.com.
For Further Information, Please Contact:
Investors:
James Hart [email protected]
Melissa B. Cummings, Chief Operating Officer of Progyny, Inc. (PGNY +0.22%), reported a sale of 3,437 shares of common stock on July 14, 2026. SEC Form 4 filing
Transaction summaryMetricValueShares sold3,437Transaction value~$109,056Post-transaction shares (directly held)69,934Post-transaction value$2.26 millionTransaction value based on SEC Form 4 weighted average sale price ($31.73); post-transaction value based on July 14, 2026, market close ($32.36).
Key questionsWhat were the primary drivers behind this equity disposition?
The transaction was structured to address both personal liquidity and tax obligations. Specifically, 2,244 shares were sold pursuant to a Rule 10b5-1 trading plan established on Dec. 19, 2025, while Progyny withheld 1,193 shares to cover tax liabilities stemming from the vesting of restricted stock units.How does this transaction affect the insider's total exposure to Progyny?
While direct holdings decreased by 5% in this filing, Cummings maintains a significant equity position of 69,934 shares. This remaining stake represents a 0.0893% ownership interest in the company, valued at $2.26 million based on the market close on the transaction date.What is the recent context of the stock's performance?
Progyny shares were priced at $32.36 at the close of July 14, 2026, the day the transaction occurred. At that time, the company had delivered a total return of 38% over the preceding 12 months. As of July 15, 2026, market close, the stock was priced at $32.34.Company OverviewMetricValueShare Price (as of market close 2026-07-15)$32.34Market Capitalization$2.5 billionRevenue (TTM)$1.3 billionNet Income (TTM)$67.7 millionCompany SnapshotProgyny operates as a specialized benefits management platform, providing comprehensive fertility and family-building solutions to employers. It features a distinctive benefits plan architecture, personalized member support services, and access to a curated network of top-tier fertility specialists, complemented by its Progyny Rx pharmaceutical offering.The company generates revenue through a subscription-based benefits management model where employers contract with Progyny to provide fertility and family-building benefits to their employees, supplemented by revenue from pharmaceutical services and ancillary offerings.Progyny primarily serves mid-to-large employers across the United States seeking to offer comprehensive fertility and family-building benefits as part of their employee benefits packages, addressing the growing demand for specialized reproductive health coverage.Progyny is a market-leading benefits management company with a $2.5 billion market capitalization, generating $1.3 billion in TTM revenue with $67.7 million in net income. The company has established a differentiated competitive position through its integrated platform combining benefits administration, personalized member services, and access to a selective network of fertility specialists, positioning it as a strategic partner for employers seeking to attract and retain talent through comprehensive family-building benefits.
What this transaction means for investorsCOO Cummings’ sales were pretty run-of-the-mill transactions. Some of it covered withholding taxes generated from restricted stock units, and the rest came from structured, pre-planned sales. Investors shouldn’t worry too much about these sales -- it wasn’t done in reaction to the stock’s price or its fundamentals.
As for Progyny’s stock, its share price has nearly doubled over the last few months after the company reported better-than-expected earnings and guidance in May. Despite losing one of its largest clients (suspected to be Amazon, though not confirmed), Progyny has rebounded nicely, delivering 1% sales growth in its most recent quarter, even though the customer accounted for 11 percentage points of a growth slowdown.
Meanwhile, Progyny’s margins have continued to improve, giving management the confidence to repurchase $200 million in shares, lowering its share count by 18% since 2024. Recently, another $200 million repurchase plan was put in place, which represents nearly 10% of its remaining shares. Progyny is a core holding for me, and I will continue adding to it over time. However, I’ll be watching customer concentration and a growing list of competitors very closely to see whether Progyny can gradually build a sustainable moat.
Key Takeaways The five stocks outperformed the S&P 500 over the past 12 weeks, four weeks and one week.VSXY surged 332.6% in a year, while its fiscal 2027 earnings estimate rose to $4.65 per share.PARR gained 131.7% in a year as its 2026 earnings estimate climbed 30.1% over the past 60 days. The U.S. stock market has remained resilient, with the S&P 500 gaining about 10% so far this year. Investors have been encouraged by steady economic data, as lower-than-expected jobless claims and stable retail sales suggest that consumer spending continues to hold up despite higher prices. The Federal Reserve reiterated that inflation remains above target but acknowledged the progress made, while stressing the central bank's commitment to making independent policy decisions.
Markets are also navigating a mix of external risks. Ongoing tensions in the Middle East and proposed U.S. tariffs on selected Brazilian imports have added uncertainty, even as Iran's release of an American prisoner has raised hopes for a gradual easing of geopolitical strains. Meanwhile, low U.S. crude inventories could keep energy prices elevated and weigh on some sectors.
Even with these headwinds, the market's ability to advance reflects underlying strength. In this environment, focusing on stocks with strong relative price strength can be a sensible strategy, as companies consistently outperforming the broader market are often better positioned to weather uncertainty and benefit when investor confidence remains intact.
At this stage, investors would be wise to consider companies such as J.B. Hunt Transport Services (JBHT - Free Report) , Progyny (PGNY - Free Report) , Bassett Furniture Industries (BSET - Free Report) , Victoria's Secret & Co. (VSXY - Free Report) and Par Pacific Holdings (PARR - Free Report) .
Relative Price Strength Strategy
Whether a stock has the potential to offer considerable returns is determined primarily by its earnings and valuation ratios. Simultaneously, it is essential to check whether its price performance exceeds its peers or the industry average.
Upon such comparison, if we find that a stock is unable to match up to wider sectoral growth despite having impressive earnings momentum or valuation multiples, it may be better to avoid it.
However, those outperforming their respective industries or benchmarks should be included in your portfolio since they have a higher chance of securing significant returns. Picking a stock that outperforms its peers ensures a winning option on your hands.
Then again, it is imperative that you determine whether or not an investment has relevant upside potential when considering stocks with significant relative price strength. Stocks delivering better than the S&P 500 for 1 to 3 months, at least, and having solid fundamentals, indicate room for growth and the best way to go about this strategy.
Finally, it is crucial to find out whether analysts are optimistic about the upcoming earnings of these companies. In order to do this, we have added positive estimate revisions for the current quarter’s (Q1) earnings to our screen. When a stock undergoes an upward revision, it leads to additional price gains.
Screening Parameters
Relative % Price change – 12 weeks greater than 0
Relative % Price change – 4 weeks greater than 0
Relative % Price change – 1 week greater than 0
(We have considered those stocks that have been outperforming the S&P 500 over the last 12 weeks, four weeks and one week.)
% Change (Q1) Est. over 4 Weeks greater than 0: Positive current-quarter estimate revisions over the last four weeks.
Zacks Rank equal to 1: Only Zacks Rank #1 (Strong Buy) stocks — that have returned more than 26% annually over the last 26 years and surpassed the S&P 500 in 23 of the last 26 years — can get through. You can see the complete list of today’s Zacks #1 Rank stocks here.
Current Price greater than or equal to $5 and Average 20-day Volume greater than or equal to 50,000: A minimum price of $5 is a good standard to screen low-priced stocks, while a high trading volume would imply adequate liquidity.
VGM Score less than or equal to B :Our research shows that stocks with a VGM Score of A or B, when combined with a Zacks Rank #1 or 2 (Buy), offer the best upside potential.
Here are five of the 12 stocks that made it through the screen:
J.B. Hunt Transport Services: It is a provider of a wide range of transportation, brokerage, and delivery services to a diverse group of customers through the United States, Canada and Mexico. The Zacks Consensus Estimate for J.B. Hunt’s 2026 earnings indicates 20.1% growth. JBHT has a VGM Score of B.
J.B. Hunt beat the Zacks Consensus Estimate for earnings in each of the last four quarters. It has a trailing four-quarter earnings surprise of roughly 9.8%, on average. JBHT shares have gained 100.4% in a year.
Progyny: Progyny provides fertility and family-building benefits for employers. Its platform combines treatment coverage, pharmacy support, a selected provider network and patient guidance, helping members access care while clients manage costs and strengthen employee satisfaction. The Zacks Consensus Estimate for 2026 earnings of Progyny indicates 7.9% growth. PGNY has a VGM Score of A.
Over the past 60 days, the Zacks Consensus Estimate for Progyny’s 2026 earnings has moved up 3.6%. The company has a market capitalization of $2.5 billion. PGNY shares have gone up 44.8% in a year.
Bassett Furniture Industries: Bassett Furniture designs, manufactures and sells home furnishings through a network of company-owned and licensed stores offering free in-home design services. The company’s expected EPS growth rate for three to five years is currently 16%, which compares favorably with the industry's growth rate of 13%. BSET has a VGM Score of B.
Over the past 60 days, the Zacks Consensus Estimate for Bassett Furniture’s fiscal 2026 earnings has moved up 7.2%. The Zacks Consensus Estimate for fiscal 2026 earnings indicates 18.7% growth. BSET shares have gained 17.2% in a year.
Victoria's Secret & Co.: It is a specialty retailer of women's intimates, sleepwear, apparel, sportswear and swimwear, and prestige fragrances and body care sold under the Victoria's Secret, PINK and Adore Me brands. Victoria's Secret’s expected EPS growth rate for three to five years is currently 27.4%, which compares favorably with the industry's growth rate of 15.5%. The company has a VGM Score of A.
VSXY has a trailing four-quarter earnings surprise of roughly 55.1%, on average. Over the past 60 days, the Zacks Consensus Estimate for Victoria’s Secret’s fiscal 2027 earnings has moved up from $3.49 per share to $4.65. VSXY’s shares have gone up 332.6% in a year.
Par Pacific Holdings: Par Pacific is an integrated energy company that produces conventional and renewable fuels across the western United States. Its operations combine refining, logistics and fuel retailing, supported by a broad transportation and storage network. The Zacks Consensus Estimate for 2026 earnings of Par Pacific indicates 136.1% growth. PARR has a VGM Score of A.
Over the past 60 days, the Zacks Consensus Estimate for Par Pacific’s 2026 earnings has moved up 30.1%. The company has a market capitalization of $3.7 billion. PARR shares have gone up 131.7% in a year.
Have you been paying attention to shares of Progyny (PGNY - Free Report) ? Shares have been on the move with the stock up 18.8% over the past month. The stock hit a new 52-week high of $32 in the previous session. Progyny has gained 24.5% since the start of the year compared to the 0.3% move for the Zacks Medical sector and the 0.2% return for the Zacks Medical Services industry.
What's Driving the Outperformance?The stock has a great record of positive earnings surprises, having beaten the Zacks Consensus Estimate in each of the last four quarters. In its last earnings report on May 7, 2026, Progyny reported EPS of $0.5 versus consensus estimate of $0.44.
For the current fiscal year, Progyny is expected to post earnings of $2.04 per share on $1.38 in revenues. This represents a 7.94% change in EPS on a 7.01% change in revenues. For the next fiscal year, the company is expected to earn $2.31 per share on $1.49 in revenues. This represents a year-over-year change of 13.24% and 8.26%, respectively.
Valuation MetricsWhile Progyny has moved to its 52-week high in the recent past, investors need to be asking, what is next for the company? A key aspect of this question is taking a look at valuation metrics in order to determine if the company has run ahead of itself.
On this front, we can look at the Zacks Style Scores, as they provide investors with an additional way to sort through stocks (beyond looking at the Zacks Rank of a security). The individual style scores for Value, Growth, Momentum and the combined VGM Score run from A through F. The idea behind the style scores is to help investors pick the most appropriate Zacks Rank stocks based on their individual investment style.
Progyny has a Value Score of C. The stock's Growth and Momentum Scores are A and B, respectively, giving the company a VGM Score of A.
In terms of its value breakdown, the stock currently trades at 15.7X current fiscal year EPS estimates, which is not in-line with the peer industry average of 15.7X. On a trailing cash flow basis, the stock currently trades at 43.4X versus its peer group's average of 10.2X. Additionally, the stock has a PEG ratio of 1.48. This isn't enough to put the company in the top echelon of all stocks we cover from a value perspective.
Zacks RankWe also need to look at the Zacks Rank for the stock, as this supersedes any trend on the style score front. Fortunately, Progyny currently has a Zacks Rank of #1 (Strong Buy) thanks to favorable earnings estimate revisions from covering analysts.
Since we recommend that investors select stocks carrying Zacks Rank of 1 (Strong Buy) or 2 (Buy) and Style Scores of A or B, it looks as if Progyny meets the list of requirements. Thus, it seems as though Progyny shares could have potential in the weeks and months to come.
How Does PGNY Stack Up to the Competition?Shares of PGNY have been soaring, and the company still appears to be a decent choice, but what about the rest of the industry? One industry peer that looks good is PACS Group, Inc. (PACS - Free Report) . PACS has a Zacks Rank of #2 (Buy) and a Value Score of B, a Growth Score of A, and a Momentum Score of B.
Earnings were strong last quarter. PACS Group, Inc. beat our consensus estimate by 19.05%, and for the current fiscal year, PACS is expected to post earnings of $2.23 per share on revenue of $5.71 billion.
Shares of PACS Group, Inc. have gained 19.4% over the past month, and currently trade at a forward P/E of 19.4X and a P/CF of 27.07X.
The Medical Services industry is in the top 41% of all the industries we have in our universe, so it looks like there are some nice tailwinds for PGNY and PACS, even beyond their own solid fundamental situation.
Progyny (PGNY - Free Report) could be a solid choice for investors given the company's remarkably improving earnings outlook. While the stock has been a strong performer lately, this trend might continue since analysts are still raising their earnings estimates for the company.
Analysts' growing optimism on the earnings prospects of this provider of fertility and family building benefits is driving estimates higher, which should get reflected in its stock price. After all, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements. Our stock rating tool -- the Zacks Rank -- is principally built on this insight.
The five-grade Zacks Rank system, which ranges from a Zacks Rank #1 (Strong Buy) to a Zacks Rank #5 (Strong Sell), has an impressive externally-audited track record of outperformance, with Zacks #1 Ranked stocks generating an average annual return of +25% since 2008.
For Progyny, there has been strong agreement among the covering analysts in raising earnings estimates, which has helped push consensus estimates considerably higher for the next quarter and full year.
The chart below shows the evolution of forward 12-month Zacks Consensus EPS estimate:
12 Month EPS
Current-Quarter Estimate RevisionsThe company is expected to earn $0.51 per share for the current quarter, which represents a year-over-year change of +6.3%.
The Zacks Consensus Estimate for Progyny has increased 7.14% over the last 30 days, as one estimate has gone higher compared to no negative revisions.
Current-Year Estimate RevisionsFor the full year, the company is expected to earn $2.04 per share, representing a year-over-year change of +7.9%.
The revisions trend for the current year also appears quite promising for Progyny, with one estimate moving higher over the past month compared to no negative revisions. The consensus estimate has also received a boost over this time frame, increasing 11.22%.
Favorable Zacks RankThe promising estimate revisions have helped Progyny earn a Zacks Rank #1 (Strong Buy). The Zacks Rank is a tried-and-tested rating tool that helps investors effectively harness the power of earnings estimate revisions and make the right investment decision.
You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
Our research shows that stocks with Zacks Rank #1 (Strong Buy) and 2 (Buy) significantly outperform the S&P 500.
Bottom LineInvestors have been betting on Progyny because of its solid estimate revisions, as evident from the stock's 18.8% gain over the past four weeks. As its earnings growth prospects might push the stock higher, you may consider adding it to your portfolio right away.
Investors might want to bet on Progyny (PGNY - Free Report) , as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of the most powerful forces impacting stock prices.
A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following years.
Individual investors often find it hard to make decisions based on rating upgrades by Wall Street analysts, since these are mostly driven by subjective factors that are hard to see and measure in real time. In these situations, the Zacks rating system comes in handy because of the power of a changing earnings picture in determining near-term stock price movements.
Therefore, the Zacks rating upgrade for Progyny basically reflects positivity about its earnings outlook that could translate into buying pressure and an increase in its stock price.
Most Powerful Force Impacting Stock PricesThe change in a company's future earnings potential, as reflected in earnings estimate revisions, and the near-term price movement of its stock are proven to be strongly correlated. That's partly because of the influence of institutional investors that use earnings and earnings estimates for calculating the fair value of a company's shares. An increase or decrease in earnings estimates in their valuation models simply results in higher or lower fair value for a stock, and institutional investors typically buy or sell it. Their transaction of large amounts of shares then leads to price movement for the stock.
For Progyny, rising earnings estimates and the consequent rating upgrade fundamentally mean an improvement in the company's underlying business. And investors' appreciation of this improving business trend should push the stock higher.
Harnessing the Power of Earnings Estimate RevisionsAs empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock movements, tracking such revisions for making an investment decision could be truly rewarding. Here is where the tried-and-tested Zacks Rank stock-rating system plays an important role, as it effectively harnesses the power of earnings estimate revisions.
The Zacks Rank stock-rating system, which uses four factors related to earnings estimates to classify stocks into five groups, ranging from Zacks Rank #1 (Strong Buy) to Zacks Rank #5 (Strong Sell), has an impressive externally-audited track record, with Zacks Rank #1 stocks generating an average annual return of +25% since 1988. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here >>>> .
Earnings Estimate Revisions for ProgynyFor the fiscal year ending December 2026, this provider of fertility and family building benefits is expected to earn $2.04 per share, which is unchanged compared with the year-ago reported number.
Analysts have been steadily raising their estimates for Progyny. Over the past three months, the Zacks Consensus Estimate for the company has increased 6.3%.
Bottom LineUnlike the overly optimistic Wall Street analysts whose rating systems tend to be weighted toward favorable recommendations, the Zacks rating system maintains an equal proportion of "buy" and "sell" ratings for its entire universe of more than 4,000 stocks at any point in time. Irrespective of market conditions, only the top 5% of the Zacks-covered stocks get a "Strong Buy" rating and the next 15% get a "Buy" rating. So, the placement of a stock in the top 20% of the Zacks-covered stocks indicates its superior earnings estimate revision feature, making it a solid candidate for producing market-beating returns in the near term.
You can learn more about the Zacks Rank here >>>
The upgrade of Progyny to a Zacks Rank #1 positions it in the top 5% of the Zacks-covered stocks in terms of estimate revisions, implying that the stock might move higher in the near term.
Momentum investing revolves around the idea of following a stock's recent trend in either direction. In "long context," investors will be essentially be "buying high, but hoping to sell even higher." With this methodology, taking advantage of trends in a stock's price is key; once a stock establishes a course, it is more than likely to continue moving that way. The goal is that once a stock heads down a fixed path, it will lead to timely and profitable trades.
While many investors like to look for momentum in stocks, this can be very tough to define. There is a lot of debate surrounding which metrics are the best to focus on and which are poor quality indicators of future performance. The Zacks Momentum Style Score, part of the Zacks Style Scores, helps address this issue for us.
Below, we take a look at Progyny (PGNY - Free Report) , which currently has a Momentum Style Score of A. We also discuss some of the main drivers of the Momentum Style Score, like price change and earnings estimate revisions.
It's also important to note that Style Scores work as a complement to the Zacks Rank, our stock rating system that has an impressive track record of outperformance. Progyny currently has a Zacks Rank of #1 (Strong Buy). Our research shows that stocks rated Zacks Rank #1 (Strong Buy) and #2 (Buy) and Style Scores of "A or B" outperform the market over the following one-month period.
You can see the current list of Zacks #1 Rank Stocks here >>>
Set to Beat the Market? In order to see if PGNY is a promising momentum pick, let's examine some Momentum Style elements to see if this provider of fertility and family building benefits holds up.
A good momentum benchmark for a stock is to look at its short-term price activity, as this can reflect both current interest and if buyers or sellers currently have the upper hand. It is also useful to compare a security to its industry, as this can help investors pinpoint the top companies in a particular area.
For PGNY, shares are up 6% over the past week while the Zacks Medical Services industry is up 1.95% over the same time period. Shares are looking quite well from a longer time frame too, as the monthly price change of 18.81% compares favorably with the industry's 3.18% performance as well.
Considering longer term price metrics, like performance over the last three months or year, can be advantageous as well. Over the past quarter, shares of Progyny have risen 76.88%, and are up 29.35% in the last year. On the other hand, the S&P 500 has only moved 10.61% and 21.48%, respectively.
Investors should also take note of PGNY's average 20-day trading volume. Volume is a useful item in many ways, and the 20-day average establishes a good price-to-volume baseline; a rising stock with above average volume is generally a bullish sign, whereas a declining stock on above average volume is typically bearish. Right now PGNY is averaging 1,299,750 shares for the last 20 days..
Earnings OutlookThe Zacks Momentum Style Score encompasses many things, including estimate revisions and a stock's price movement. Investors should note that earnings estimates are also significant to the Zacks Rank, and a nice path here can be promising. We have recently been noticing this with PGNY.
Over the past two months, 1 earnings estimate moved higher compared to none lower for the full year. This revision helped boost PGNY's consensus estimate, increasing from $1.97 to $2.04 in the past 60 days. Looking at the next fiscal year, 1 estimate has moved upwards while there have been no downward revisions in the same time period.
Bottom LineGiven these factors, it shouldn't be surprising that PGNY is a #1 (Strong Buy) stock and boasts a Momentum Score of A. If you're looking for a fresh pick that's set to soar in the near-term, make sure to keep Progyny on your short list.
Mark S. Livingston, Chief Financial Officer of Progyny (PGNY +0.45%), reported the sale of 8,275 shares of common stock in an open-market transaction on May 20, 2026, as disclosed in an SEC Form 4 filing.
Transaction summaryMetricValueShares sold (direct)8,275Transaction value$211,000Post-transaction shares (direct)79,063Post-transaction value (direct ownership)$2.03 millionTransaction value based on SEC Form 4 reported price ($25.50); post-transaction value based on May 20, 2026 trade-date close price.
Key questionsHow meaningful was this sale as a proportion of Livingston's direct holdings?
This transaction represented 9.47% of Livingston's direct position, a moderate reduction consistent with the cadence of his prior open-market sales.Did the sale affect indirect or derivative holdings?
No indirect or derivative holdings were reported; the activity was limited to directly held common shares, leaving Livingston with 79,063 shares post-transaction.What does the transaction reveal about selling cadence and capacity?
Recent sales have corresponded to a decline in total available shares, with remaining direct holdings now at 43.2% of the level held in July 2023, indicating that trade size reductions are a function of reduced capacity rather than a change in selling intent.Company overviewMetricValueRevenue (TTM)$1.29 billionNet income (TTM)$67.69 millionEmployees675Price (as of market close 5/20/26)$25.64* 1-year performance metrics are calculated using May 20th, 2026 as the reference date.
Company snapshotProgyny offers fertility and family building benefits solutions, including differentiated plan designs, member support services, a selective network of fertility specialists, and an integrated pharmacy benefits platform.It operates a benefits management model, generating revenue through employer-sponsored health benefit programs and pharmacy solutions.The company serves employers across the United States seeking fertility and family-building benefits for their employees.Progyny is a leading provider of fertility and family building benefits, leveraging a data-driven platform and selective provider network to deliver tailored solutions for employers. The company’s integrated approach combines plan design, member support, and pharmacy management, positioning it as a differentiated player in the healthcare benefits space.
What this transaction means for investorsThe May 20 sale of Progyny stock by CFO Mark Livingston came at a time when shares were on the upswing. His disposition at $25.50 per share was close to the 52-week high of $28.75 reached in January. He subsequently sold additional shares in June.
Even so, Livingston’s sales are not a red flag for investors. They were non-discretionary transactions performed as part of a pre-arranged Rule 10b5-1 trading plan, adopted back in August of 2025. Such plans are often implemented by insiders to avoid accusations of trading based on insider information.
Progyny lost a major customer, but its shares rose in the second quarter after the company delivered strong full-year guidance for 2026. It projects revenue will increase between 6% to 9% year over year.
Excluding the sales delivered by the one large client from 2025 totals, the year-over-year revenue growth would be a whopping 10% to 13%. This suggests Progyny is seeing increased income from other customers.
Robert Izquierdo has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Progyny. The Motley Fool has a disclosure policy.
On June 12, 2026, Progyny Inc PGNY shares rose 3.8% to $26.63. The stock has traded within a 52-week range of $16.10 to $28.75, indicating considerable volatility over the past year. This recent price movement reflects a growing interest in the stock.
GF Value™ verdict: Current price is $26.63, which is 5.0% below the GF Value™ of $28.04.GF Score™: 92/100, indicating a strong overall rating.Most notable signal: Financial strength, rated at 8/10. Is PGNY Overvalued or Undervalued? Progyny Inc's current price of $26.63 is slightly below its GF Value™ of $28.04, suggesting that the stock is undervalued by approximately 5.0%. This margin of safety indicates a potential opportunity for investors looking for stocks that are trading below their intrinsic value. The GF Valuation label categorizes the stock as fairly valued, which aligns with its current trading position just below the calculated fair value. GF Value™ is GuruFocus' proprietary measure of intrinsic value, calculated from historical trading multiples, past business growth, and future performance estimates.
While the stock presents an opportunity, it is important to consider that market conditions can change swiftly. Investors should remain cautious, especially in light of the overall market environment and Progyny's performance over the last three years, which has seen a decline of 12.3%.
How Does PGNY's Valuation Compare to Its History? Metric Current Historical P/E (TTM) 34.6x 58.0x Forward P/E 21.2x N/A Progyny's current P/E (TTM) of 34.6x is significantly below its 5-year median P/E of 58.0x, indicating that the stock is trading at a lower valuation compared to its historical averages. The forward P/E of 21.2x further emphasizes this trend, suggesting potential for increased earnings in the future. This P/E analysis agrees with the GF Value™ verdict, reinforcing the notion that the stock is undervalued relative to its historical performance.
What Does PGNY's GF Score™ Tell Us? Metric Rating GF Score™ 92 Financial Strength 8/10 Profitability 8/10 Growth 10/10 Valuation 10/10 Momentum 5/10 Progyny's GF Score™ of 92/100 illustrates a strong overall performance in financial health, profitability, growth, and valuation, with particularly high ratings in growth (10/10) and valuation (10/10). The weakest area appears to be momentum, rated at 5/10, suggesting that while the stock has potential, its recent performance may not exhibit the same strength as its financial fundamentals. This combination suggests that while the company is fundamentally strong, it may face challenges in maintaining upward momentum in the short term.
What Are Insiders Doing with PGNY Stock? In the last three months, insiders have sold approximately $1.0 million worth of shares with no reported buying activity. This selling pattern may raise some concerns among potential investors, as it could indicate a lack of confidence from those closest to the company. However, insider selling can also occur for various reasons unrelated to the company's performance or outlook.
Overall, the absence of insider buying in conjunction with recent selling activity suggests caution, as it may reflect a sentiment among insiders regarding the stock's current valuation or future prospects.
What This Means for Investors Based on the current assessment, Progyny Inc PGNY is considered undervalued with a GF Value™ of $28.04 compared to its current price of $26.63. While the stock shows potential based on its strong financial fundamentals, investors should remain aware of the insider selling activity and the recent volatility in its performance.
For the complete analysis, visit the Progyny Inc PGNY stock page. You can also explore the GF Value™ page for detailed valuation methodology, or use the GuruFocus Stock Screener to find similar opportunities.
Frequently Asked Questions What is PGNY's GF Score™?
PGNY has a GF Score™ of 92/100, indicating a strong overall assessment based on key aspects of financial health, profitability, growth, valuation, and momentum.
Is PGNY overvalued or undervalued?
PGNY is currently undervalued, with a GF Value™ of $28.04 compared to its current price of $26.63, suggesting a 5.0% margin of safety.
What is PGNY's P/E ratio?
PGNY's P/E (TTM) is 34.6x, which is significantly below its 5-year median P/E of 58.0x, indicating it is trading at a lower valuation compared to its historical levels.
This stock alert was generated using automated technology and GuruFocus financial data to provide readers with timely and accurate market reporting. This content was reviewed by GuruFocus editorial team prior to publication. Please send any questions or comments about this story to [email protected].
NEW YORK, April 16, 2026 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a global leader in women's health and family building solutions, today announces Progyny Select, the industry's first fully insured, comprehensive supplemental fertility and family building plan. Available in the U.S., Progyny Select enables small employers to have access to fertility solutions in a fixed premium model.
NEW YORK, April 23, 2026 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a global leader in women's health and family building solutions, will report its financial results for the quarterly period ended March 31, 2026, after the close of the market on Thursday, May 7, 2026.
Progyny, Inc. (NASDAQ: PGNY - Get Free Report) has been given an average recommendation of "Moderate Buy" by the thirteen analysts that are presently covering the stock, MarketBeat Ratings reports. Four research analysts have rated the stock with a hold recommendation and nine have assigned a buy recommendation to the company. The average 12 month target
Investors with an interest in Medical Services stocks have likely encountered both Progyny (PGNY) and Alignment Healthcare (ALHC). But which of these two stocks is more attractive to value investors?
Progyny (PGNY) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Reports Record First Quarter Revenue of $328.5 MillionEarly Selling Season Activity Reflects Robust Demand for Women's Health and Family Building SolutionsReturned Value to Shareholders Through Repurchase of 8.8 Million Shares to Date Since November NEW YORK, May 07, 2026 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY) (“Progyny” or the “Company”), a global leader in women's health and family building solutions, today announced its financial results for the three-month period ended March 31, 2026 (“the first quarter of 2026”), as compared to the three-month period ended March 31, 2025 (“the first quarter of 2025” or “the prior year period”). “We're pleased with the strong start to the year, as member engagement trended to the higher end of our expectations, reflecting that people are pursuing the services they need in order to address their family building and overall health and well-being goals,” said Pete Anevski, Chief Executive Officer of Progyny.
Progyny (PGNY) came out with quarterly earnings of $0.5 per share, beating the Zacks Consensus Estimate of $0.44 per share. This compares to earnings of $0.48 per share a year ago.
Progyny NASDAQ: PGNY reported what management called a strong start to 2026, with first-quarter revenue reaching a record level and profitability exceeding expectations amid continued investments in its platform and member experience.
NEW YORK, May 11, 2026 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a global leader in women's health and family building solutions, today announced that Progyny's Chief Executive Officer, Pete Anevski, and Chief Financial Officer, Mark Livingston, will participate in a fireside chat at the BofA Securities 2026 Health Care Conference on Tuesday, May 12, 2026, at 11:20 A.M. Pacific Time / 2:20 P.M. Eastern Time.
These highly ranked medical stocks have been capitalizing on their sales expansion, and their defensive or secular growth profiles could become even more attractive if an economic downturn emerges.
For growth investors seeking exposure to a differentiated healthcare disruptor with strong secular tailwinds, Progyny (PGNY) stock deserves a close look.
On May 21, 2026, Progyny Inc (PGNY) shares fell 3.8%, closing at $24.69. This decline comes amidst a 52-week range where the stock has seen a high of $28.75 and
NEW YORK, May 26, 2026 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a global leader in women's health and family building solutions, today announced that its Board of Directors has approved a share repurchase program to repurchase up to $200 million of its common stock. The program will be funded through available cash balances.
Patients increasingly say human connection and advocacy are essential to reducing stress and improving the care experience Patients increasingly say human connection and advocacy are essential to reducing stress and improving the care experience
